Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets ...
The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period. PD-L1 ...
EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors What Is The Expected Cagr For The PD-L1 And ...
PARSIPPANY, NJ--(Marketwired - Feb 3, 2016) - Diaceutics Group, a dedicated integrator in personalized and precision medicine, enabling the effective combination of therapies and diagnostics into the ...
Lunit and Roche, both medical diagnostics manufacturing companies, have announced a partnership to integrate Lunit’s SCOPE PD-L1 AI diagnosis tool with Roche’s Digital Pathology platform. The ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results